# ANEB (Anebulo Pharmaceuticals, Inc.) - SEC EDGAR Financial Statements

> Anebulo Pharmaceuticals, Inc. reported $9.42M in total assets and a net loss of $7.98M through June 30, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/ANEB
- Markdown: https://convexityos.com/fundamentals/ANEB.md
- SEC CIK: 0001815974
- Reporting currency: USD
- Latest filing period: December 31, 2025
- Last synced: Nov 21, 2026, 05:06 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001815974&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Jun 30, 2025 |
| Operating Income | FY 2025 | -$9.10M | Operating profit |
| Net Income | FY 2025 | -$7.98M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$0.19 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Dec 31, 2025 | $9.04M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Research & Development | $4.30M | $3.55M | $5.60M | $2.96M | $2.27M |
| Total Operating Expenses | $9.22M | $8.31M | $11.78M | $6.83M | $3.61M |
| **Operating Income** | -$9.22M | -$8.31M | -$11.78M | -$6.83M | -$3.61M |
| Interest Income | $258K | $249K | $92K | $7.3K | $1.0K |
| Interest Expense | $400K | $200K | -- | -- | $12K |
| Income Before Tax | -- | -- | -- | -- | -$3.61M |
| **Net Income** | -$8.48M | -$8.20M | -$11.73M | -$6.83M | -$30.25M |
| Basic EPS | -$0.25 | -$0.32 | -$0.47 | $0.29 | -$2.83 |
| **Diluted EPS** | -$0.25 | -$0.32 | -$0.47 | $0.29 | -$2.83 |
| Basic Shares Outstanding | 33.8M | 25.8M | 25.1M | 23.3M | 13.6M |
| Diluted Shares Outstanding | 33.8M | 25.8M | 25.1M | 23.3M | 13.6M |

### Income Statement (Quarterly)

| Line Item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $1.16M | $810K | $1.13M | $638K | $1.22M | $1.31M | $468K | $748K |
| Total Operating Expenses | $2.62M | $2.26M | $2.33M | $1.89M | $2.59M | $2.41M | $1.34M | $1.66M |
| **Operating Income** | -$2.62M | -$2.26M | -$2.33M | -$1.89M | -$2.59M | -$2.41M | -$1.34M | -$1.66M |
| Interest Income | $85K | $110K | $123K | $102K | $7.1K | $26K | $50K | $68K |
| Interest Expense | $17K | $17K | $300K | $100K | $100K | $100K | -- | $60K |
| **Net Income** | -$2.00M | -$2.16M | -$2.14M | -$1.68M | -$2.46M | -$2.20M | -$1.35M | -$1.65M |
| Basic EPS | -$0.05 | -$0.05 | -- | -$0.04 | -$0.09 | -$0.08 | -- | -$0.06 |
| **Diluted EPS** | -$0.05 | -$0.05 | -- | -$0.04 | -$0.09 | -$0.08 | -- | -$0.06 |
| Basic Shares Outstanding | 41.1M | 41.1M | -- | 41.1M | 27.4M | 25.9M | -- | 25.9M |
| Diluted Shares Outstanding | 41.1M | 41.1M | -- | 41.1M | 27.4M | 25.9M | -- | 25.9M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $11.63M | $3.09M | $11.25M | $14.55M | $19.99M | $3.02M |
| **Cash & Short-Term Investments** | $11.63M | $3.09M | $11.25M | $14.55M | $19.99M | $3.02M |
| **Total Current Assets** | $11.96M | $3.51M | $11.67M | -- | -- | $3.03M |
| Other Non-Current Assets | $183K | $565K | -- | -- | -- | -- |
| **Total Non-Current Assets** | $183K | $565K | $0 | -- | -- | $0 |
| **Total Assets** | $12.15M | $4.07M | $11.67M | $15.58M | $21.65M | $3.03M |
| Accounts Payable | $224K | $156K | $535K | $381K | $110K | -- |
| **Total Current Liabilities** | -- | -- | -- | -- | -- | $224K |
| **Total Non-Current Liabilities** | -- | -- | -- | -- | -- | $0 |
| **Total Liabilities** | $488K | $261K | $1.07M | $513K | $242K | $224K |
| Common Stock | $41K | $26K | $26K | $23K | $23K | $12K |
| Retained Earnings | -$73.89M | -$65.40M | -$57.20M | -$45.47M | -$38.64M | -$183K |
| **Total Stockholders' Equity** | $11.66M | $3.81M | $10.60M | $15.07M | $21.41M | -$171K |
| Total Equity | $11.66M | $3.81M | $10.60M | $15.07M | $21.41M | -$171K |

### Balance Sheet (Quarterly)

| Line Item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $9.04M | $10.35M | $11.63M | $13.28M | $15.00M | $1.40M | $3.09M | $5.15M |
| **Cash & Short-Term Investments** | $9.04M | $10.35M | $11.63M | $13.28M | $15.00M | $1.40M | $3.09M | $5.15M |
| **Total Current Assets** | $9.27M | $10.54M | $11.96M | $13.81M | $15.40M | $1.96M | $3.51M | $5.37M |
| Other Non-Current Assets | $148K | $166K | $183K | $201K | $446K | $505K | $565K | $625K |
| **Total Non-Current Assets** | $148K | $166K | $183K | $201K | $446K | $505K | $565K | $625K |
| **Total Assets** | $9.42M | $10.70M | $12.15M | $14.01M | $15.84M | $2.47M | $4.07M | $6.00M |
| Accounts Payable | $555K | $608K | $224K | $428K | $320K | $252K | $156K | $385K |
| **Total Liabilities** | $1.49M | $964K | $488K | $546K | $879K | $569K | $261K | $1.01M |
| Common Stock | $41K | $41K | $41K | $41K | $41K | $26K | $26K | $26K |
| Retained Earnings | -$78.05M | -$76.05M | -$73.89M | -$71.74M | -$70.07M | -$67.60M | -$65.40M | -$64.05M |
| **Total Stockholders' Equity** | $7.94M | $9.74M | $11.66M | $13.46M | $14.96M | $1.90M | $3.81M | $4.99M |
| Total Equity | $7.94M | $9.74M | $11.66M | $13.46M | $14.96M | $1.90M | $3.81M | $4.99M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Net Income | -$8.48M | -$8.20M | -$11.73M | -$6.83M | -$30.25M |
| Stock-Based Compensation | $1.45M | $759K | $885K | $481K | $200K |
| Change in Payables | $68K | -$378K | $154K | $271K | $110K |
| **Operating Cash Flow** | -$6.35M | -$8.09M | -$9.68M | -$5.44M | -$4.87M |
| Common Stock Issued | $15.00M | -- | $6.65M | -- | $20.60M |
| **Financing Cash Flow** | $14.88M | -$62K | $6.38M | -- | $21.83M |
| **Net Change in Cash** | $8.53M | -$8.15M | -$3.30M | -$5.44M | $16.96M |

### Cash Flow Statement (Quarterly)

| Line Item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$2.00M | -$2.16M | -$2.14M | -$1.68M | -$2.46M | -$2.20M | -$1.35M | -$1.65M |
| Stock-Based Compensation | $199K | $238K | $340K | $300K | $564K | $287K | $177K | $200K |
| Change in Payables | -$53K | $383K | -$203K | $146K | $30K | $96K | -$228K | $66K |
| **Operating Cash Flow** | -$1.31M | -$1.27M | -$1.65M | -$1.60M | -$1.41M | -$1.69M | -$2.05M | -$1.50M |
| **Net Change in Cash** | -$1.31M | -$1.27M | -$1.65M | -$1.72M | $13.59M | -$1.69M | -$2.05M | -$1.50M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -72.8% | -215.1% | -110.7% | -45.3% | -141.3% |
| Return on Assets (ROA) | -69.9% | -201.4% | -100.5% | -43.8% | -139.7% |
| EPS Growth (YoY) | -- | -- | -262.1% | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -100.5% | -86.7% | -72.8% | -57.1% | -51.2% | -417.2% | -215.1% | -187.5% |
| Return on Assets (ROA) | -84.7% | -78.9% | -69.9% | -54.9% | -48.4% | -321.0% | -201.4% | -155.9% |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
